Based on these very early RA patients from the OPERA cohort, we propose that an initial high level of CXCL13 could be a potential indicator that the patients are more treatment-responsive and thereby within the so-called ‘window of opportunity’. This evidence concerns the gene CXCL13 and rheumatoid arthritis.